Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
FDA Approvals
FDA Approvals
Gavreto Received Regular FDA Approval for Patients With Non–Small Cell Lung Cancer and RET Gene Fusion
Read More
FDA Approvals
Lonsurf Received a New Indication, in Combination With Bevacizumab, for Previously Treated Metastatic Colorectal Cancer
Read More
FDA Approvals
Jemperli Plus Chemotherapy Now FDA Approved for Front-Line Treatment of dMMR or MSI-H Endometrial Cancer
Read More
FDA Approvals
Vanflyta Now Approved for Newly Diagnosed FLT3-ITD–Positive AML
Read More
FDA Approvals
Talzenna Received a New Indication, With Enzalutamide, for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Mutation
Read More
FDA Approvals
Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer
Read More
FDA Approvals
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
Read More
FDA Approvals
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
Read More
FDA Approvals
Pemazyre Receives New Indication for FGFR1-Positive Myeloid/Lymphoid Neoplasms
Read More
FDA Approvals
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
Read More
1
2
3
4
5
6
7
Page 4 of 18
Results 31 - 40 of 180